The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
A Randomised Study To Optimise Clinical Outcomes In Patients With FLT3 Mutant AML
Funder
National Health and Medical Research Council
Funding Amount
$1,169,549.00
Summary
Acute myeloid leukaemia is a devastating blood cancer which affects almost 1000 Australians annually. One quarter have a mutation affecting a gene called FLT3, which results in aggressive leukaemia rarely cured by chemotherapy alone. Dr Andrew Wei from the Alfred Hospital will lead a nationwide randomised clinical trial through the Australasian Leukaemia and Lymphoma Group network to investigate whether a targeted FLT3 inhibitor small molecule called Sorafenib will improve outcomes for patients ....Acute myeloid leukaemia is a devastating blood cancer which affects almost 1000 Australians annually. One quarter have a mutation affecting a gene called FLT3, which results in aggressive leukaemia rarely cured by chemotherapy alone. Dr Andrew Wei from the Alfred Hospital will lead a nationwide randomised clinical trial through the Australasian Leukaemia and Lymphoma Group network to investigate whether a targeted FLT3 inhibitor small molecule called Sorafenib will improve outcomes for patients with this poor risk blood cancer.Read moreRead less
Treating Insomnia In Patients With Co-existing Obstructive Sleep Apnea
Funder
National Health and Medical Research Council
Funding Amount
$260,046.00
Summary
Obstructive sleep apnea (OSA) and insomnia commonly coexist in the same patient, and can affect how patients adhere to treatment for their OSA. Insomnia can be effectively treated by a clinical psychologist using a technique known as cognitive behaviour therapy (CBT), but it is currently unclear whether this is effective in patients who also have OSA. This research project will investigate whether treatment of insomnia using CBT in patients who have OSA will improve health outcomes.
Treating Insomnia Co-morbid With Obstructive Sleep Apnoea: A Randomized Controlled Clinical Effectiveness Trial.
Funder
National Health and Medical Research Council
Funding Amount
$600,869.00
Summary
Obstructive Sleep Apnoea (OSA) is a common but serious sleep disorder. Continuous positive airways pressure (CPAP) therapy can be very effective in treating OSA. We have found that many patients with OSA also suffer from insomnia, and this can make it hard for them to begin CPAP therapy and hard for them to stick to it. This trial will examine the effect of treating insomnia concurrently with CPAP, with the expectation that overall treatment outcomes will improve.
Continuous Positive Airway Pressure For Obstructive Sleep Apnoea In Quadriplegia: A Randomised Trial
Funder
National Health and Medical Research Council
Funding Amount
$307,677.00
Summary
Each year in Australia 260 people sustain a SCI, with over half losing full function in their arms and legs (quadriplegia). In addition to the primary disability, there is a very high rate of Obstructive Sleep Apnoea (OSA). This project is a multi-national randomized controlled trial to treat OSA in acute injury with a nasal mask during sleep. The study will determine if we can help people live better after injury by improving sleep, quality of life, memory and attention.